LIR Life Sciences Corp.
SKNY
CNSX
| 10/31/2025 | 07/31/2025 | 10/31/2024 | |||
|---|---|---|---|---|---|
| Net Income | -141.20K | -102.00K | -30.70K | ||
| Total Depreciation and Amortization | 1.00K | 800.00 | -- | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | -100.00 | 100.00 | -- | ||
| Change in Net Operating Assets | 136.40K | 66.00K | -36.90K | ||
| Cash from Operations | -4.00K | -35.10K | -67.60K | ||
| Capital Expenditure | -- | -- | -- | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | 0.00 | -76.40K | -- | ||
| Cash from Investing | 0.00 | -76.40K | -- | ||
| Total Debt Issued | 5.00K | 35.00K | 0.00 | ||
| Total Debt Repaid | -- | -- | -- | ||
| Issuance of Common Stock | 1.07M | -- | -- | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -- | -- | -- | ||
| Cash from Financing | 773.00K | 25.50K | 0.00 | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | 0.00 | ||
| Net Change in Cash | 768.90K | -86.10K | -67.60K | ||